Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - June 2017

Recent News

Jun. 17, 2017Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant LymphomaPrinter Friendly Version
Jun. 14, 2017Court Decides It Lacks Jurisdiction Before FDA Approval OccursPrinter Friendly Version
Jun. 06, 2017Juno Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare ConferencePrinter Friendly Version
Jun. 05, 2017Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin LymphomaPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Past Events

There are no past events to display.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
JUNO (Common Stock)
Change Stock is Up 0.65 (2.24%)
Data as of Jul. 21, 2017 4:00 p.m. ET